Emerald Health Therapeutics’ Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US
January 29 2019 - 6:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH;
OTCQX:EMHTF) today announced that its joint venture partner, San
Diego-based Emerald Health Bioceuticals (“EHB”), has launched its
award-winning Endo products in Whole Foods Markets across the
United States, highlighting the unique positioning and opportunity
for this product line when it is launched in Canada in 2019.
The joint venture, called Emerald Health Naturals (“EHN”),
secured Canadian distribution rights for this product line that was
developed to support the body’s endocannabinoid system (ECS), but
which does not contain cannabis. Canadian retailers have not been
announced.
In December 2018, EHT received natural product
numbers (NPNs) from Health Canada to sell Endo in Canada. EHN is
owned 51% by Emerald and 49% by EHB.
“For the Endo products to be embraced by
retailers with such high standards of retail excellence and broad
reach like Whole Foods Market in the US is an important milestone
for this unique natural health supplement line,” said Gaetano
Morello, ND, CEO of Emerald Health Naturals. “A non-cannabis
product line capable of nurturing the endocannabinoid system is a
unique product category - and it is one that is garnering
significant attention in the US. We aim to similarly build strong
distribution channels with top retailers in Canada in 2019.”
“With 60% of cannabis users also being users of
natural health products, we have a two-pronged opportunity in
Canada to build a stand-alone market for the Endo product line for
cannabis non-users as well as achieve Emerald brand recognition
among cannabis users in channels unable to carry cannabis
products,” said Avtar Dhillon, President and Executive Chairman,
Emerald Health Therapeutics. “Natural health product stores,
pharmacies, and even grocery stores may all be potential outlets
for the Endo product line. We look forward to offering the
proprietary Endo products to Canadian consumers this year.”
Endo nutritional supplements feature
PhytoCann-Complex™, a proprietary formulation consisting of
non-cannabis, non-psychoactive, plant-based bioactive compounds
that support the body’s endocannabinoid system. The role of the ECS
as the body’s innate balancing mechanism is key to the regulation
of everything from appetite, energy, metabolism, fertility and
immunity to sleep, mood, pain perception and memory. The Endo
product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss
and Endo Inflame, and they are intended to naturally address the
body’s response to conditions such as stress, anxiety, restless
sleep and pain, and foster overall health and wellness.
Over the last year, EHB has secured multiple
distribution and sales channels for the Endo product line in the
United States and internationally, ranging from small independent
natural health product retailers to nationwide grocery store chains
like Whole Foods Market, as well as Amazon.com.
About The Endo Product Line*
Endo Brain - Naturally supports mental acuity and
cognition by nurturing and nourishing your endocannabinoid
system.
Endo Sleep - Enjoy restful and
rejuvenating sleep by naturally supporting your endocannabinoid
system, optimal health and vitality.
Endo Calm - Naturally address
your body’s response to stress and anxiety by supporting your
endocannabinoid system and optimal health and vitality.
Endo Bliss - Naturally supports
a positive outlook and resistance to daily pressures by nurturing
and nourishing your endocannabinoid system. Endo Inflame
- Naturally promote your body’s healthy response to pain
and inflammation by supporting your endocannabinoid system for
optimal health and vitality. * The statements made herein have not
been evaluated by Health Canada or the Food and Drug
Administration. This product is not intended to diagnose, treat,
cure or prevent any disease.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint
venture in BC is completing the conversion of its 1.1 million
square foot (25 acre) greenhouse for cannabis cultivation in the
Lower Mainland and its Verdélite operation in Québec is completing
the build out of its 75,000 square feet indoor cultivation
facility. Commercial production is expanding in both facilities.
Emerald secured over 500 acres of hemp harvest in 2018 and has
contracted for approximately 1000 acres in 2019 to 2022, with the
objective of extracting low-cost cannabidiol (CBD). Emerald’s team
is highly experienced in life sciences, product development,
large-scale agri-business, and marketing, and is focused on
developing proprietary, value-added cannabis products for medical
and adult-use customers. Emerald is part of the Emerald Health
group, which represents a broad array of companies focused on
developing pharmaceutical, botanical, and nutraceutical products
developed to provide wellness and medical benefits by interacting
with the human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more
information or contact:Rob Hill, Chief Financial Officer(800) 757
3536 Ext. #5
Investor Relations(800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is definedin the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include completion of the joint venture and obtaining exclusive
Canadian distribution rights; establishing a brand; launch of the
Endo line in 2019; sales of non-cannabis products; development of
sales channels; expansion of permitted sales of cannabis;
leveraging of distribution channels; development of new products;
the benefits and effects of certain products; production capacity
of various facilities; and receipt of hemp deliveries.
Actual results may vary from forward-looking
statements. We cannot guarantee that any forward-looking statement
will materialize, and readers are cautioned not to place undue
reliance on these forward-looking statements. These forward-looking
statements involve risks and uncertainties related to, among other
things, failure to obtain necessary financing; failure to settle
final documentation; failure to obtain regulatory approvals;
results of production and sale activities; results of scientific
research; regulatory changes; changes in prices and costs of
inputs; demand for labour; demand for products; future distribution
agreements; failure of counterparties to perform contractual
obligations; as well as the risk factors described in the Company’s
annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jul 2023 to Jul 2024